The special meeting is July 16, 2026 — 10 days away. The supplemental disclosures are a standard response to merger litigation and do not change deal economics. The two shareholder lawsuits seek to enjoin the merger but the company has not been enjoined. Monitor for any preliminary injunction ruling before the vote; absent that, the deal is on track for Q3 close. The stock should trade near the deal price with a small spread reflecting litigation and timing risk.
Price Chart
Executive Summary
Cross Country Healthcare filed supplemental disclosures to its merger proxy statement in response to two shareholder lawsuits (Malone and Walsh actions) and multiple demand letters challenging the adequacy of disclosures related to the pending take-private acquisition by Knox Lane (KL Criss Cross Intermediate, LLC). The supplemental disclosures add details about post-closing consulting/board discussions between Knox Lane and certain executives (Mr. Burns, Ms. Ball, Mr. Clark) and expand the BofA Securities fairness opinion financial analyses. The special meeting to approve the merger is scheduled for July 16, 2026, with closing expected in Q3 2026. The lawsuits seek to enjoin the merger but the company believes the claims are without merit.
Key Financial Metrics
Key Facts
- Special meeting of stockholders to approve the merger is scheduled for July 16, 2026.
- Two lawsuits (Malone and Walsh actions) filed in New York state court on June 23 and June 24, 2026, alleging the proxy statement is materially incomplete.
- Company voluntarily supplemented the proxy statement with additional disclosures regarding post-closing consulting/board discussions with executives (Mr. Burns, Ms. Ball, Mr. Clark) and expanded BofA Securities fairness opinion details.
- Company believes the lawsuits are without merit and denies any disclosure deficiencies.
- Merger expected to close in Q3 2026, subject to stockholder approval and other conditions.
- BofA Securities applied EV/EBITDA multiples of 4.8x-7.5x (public comps) and 9.0x-11.5x (precedent transactions) in its fairness analysis.
- Net cash at closing estimated at approximately $106.2 million; fully-diluted shares estimated at ~33.006 million.
Financial Impact
No new financial terms disclosed. Supplemental disclosures add detail to BofA fairness opinion: net cash ~$106.2M, fully-diluted shares ~33.006M, analyst price targets discounted to $9.09-$13.64/share.
Risk Factors
- Shareholder lawsuits (Malone and Walsh actions) could result in an injunction delaying or blocking the merger.
- Stockholder vote on July 16 may fail to approve the merger.
- Additional demand letters or lawsuits could emerge before the special meeting.
- Deal completion expected in Q3 2026 but subject to remaining conditions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0000950103-26-010221 |
| Document: 0000950103-26-010221-index-headers.html | 0000950103-26-010221 |
| Document: 0000950103-26-010221-index.html | 0000950103-26-010221 |
| Document: 0000950103-26-010221.txt | 0000950103-26-010221 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 6, 2026 16w ago | 425 | $13.20 | awaiting T+20 | — | — |
Jul 6, 2026 16w ago | 8-K | $13.20 | awaiting T+20 | — | — |
Jun 15, 2026 19w ago | DEFM14A | $13.18 $13.22 | ▲ +0.30% | ▲ +0.10% | — |
Jun 3, 2026 20w ago | PREM14A | $13.19 $13.20 | ▲ +0.08% | ▲ +1.45% | — |
May 7, 2026 24w ago | DEFA14A | $13.18 $13.18 | · 0.00% | ▼ −0.02% | — |
May 7, 2026 24w ago | DEFA14A | $13.18 $13.18 | · 0.00% | ▼ −0.02% | — |
May 7, 2026 24w ago | 8-K | $13.18 $13.18 | · 0.00% | ▼ −0.02% | — |
May 7, 2026 24w ago | 8-K | $13.09 $13.12 | ▲ +0.23% | ▼ −2.91% | — |
Apr 17, 2026 27w ago | 8-K | $9.96 $13.10 | ▲ +31.53% | ▲ +27.32% | — |
Mar 4, 2026 33w ago | 8-K | $9.89 $9.18 | ▲ +7.18% | ▲ +3.39% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers